Modified Edmonton Symptom Assessment System Including Constipation and Sleep: Validation in Outpatients With Cancer

Hannon, Breffni; Dyck, Martin; Pope, Ashley; Swami, Nadia; Banerjee, Subrata; Mak, Ernie; Bryson, John; Rodin, Gary; Ridley, Julia; Lo, Chris; Le, Lisa W.; Zimmermann, Camilla

doi:10.1016/j.jpainsymman.2014.10.013

Cited by 84 publications

(76 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, follow‐up visits are also important among cancer survivors for identification of symptoms suggestive of late effects of treatment. The addition of patient‐reported outcome measures to follow‐up assessments, such as the Edmonton Symptom Assessment System and Distress Assessment and Response Tool, allows for health care teams to provide an individualized approach to meet patients' cancer‐related needs . Routine follow‐up in centers using patient‐reported outcomes may help identify problems early, allowing for early intervention, thus improving the patient experience and overall quality of care received.…”

Section: Discussionmentioning

confidence: 99%

Adherence to guideline‐recommended process measures for squamous cell carcinoma of the head and neck in Ontario: Impact of surgeon and hospital volume

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Adherence to guideline‐recommended process measures for squamous cell carcinoma of the head and neck in Ontario: Impact of surgeon and hospital volume

et al. 2016

View full text Add to dashboard Cite

show abstract

“…pain, fatigue, nausea, depression, anxiety, drowsiness, shortness of breath, appetite, feelings of well-being and sleep) at both the first and second study visits using the Edmonton Symptom Assessment Scale (ESAS). ESAS is a validated symptom battery that uses a 0 (no symptom) to 10 (worst intensity) point numeric rating scale to examine the average intensity of each symptom over the past 24 hours [16, 17]. It has been psychometrically and linguistically validated and is available in the languages in respective countries (i.e.…”

Section: Methodsmentioning

confidence: 99%

“…The ESAS is a validated symptom battery that uses a numeric rating scale of 0 (no symptoms) to 10 (worst intensity) to examine the average intensity of each symptom over the past 24 hours. 16,17 It has been psychometrically and linguistically validated and is available in the languages of the respective countries in the current study (ie, English, Arabic, Portuguese, Spanish, and Hindi). [18][19][20][21][22][23] For each of the 10 symptoms, we assessed the PSG at the time of the second study visit by asking the patient "At what level would you feel comfortable with this symptom?"…”

Section: Participantsmentioning

confidence: 99%

Personalized symptom goals and response in patients with advanced cancer

Hui

Park

Shamieh

et al. 2016

Cancer

View full text Add to dashboard Cite

Background Improving symptoms is a major goal of cancer medicine; however, symptom response is often based on group differences and not individualized. We examined the personalized symptom goal (PSG) for 10 common symptoms in patients with advanced cancer, and identified the factors associated with PSG response. Methods In this prospective longitudinal multicenter study, patients from 5 tertiary care hospitals rated the intensity of 10 symptoms using a 0-10 numeric rating scale at first clinic visit and then a second visit 14-34 days later. PSG was determined for each symptom by asking patients: “At what level would you feel comfortable with this symptom?” using the same 0-10 scale for symptom intensity. PSG response was defined as symptom intensity at second visit less than or equal to PSG. Results Among 728 patients, the median PSG was 1 for nausea, 2 for depression, anxiety, drowsiness, well being, dyspnea and sleep, and 3 for pain, fatigue, and appetite. A greater proportion of patients achieved a PSG response in second visit compared to first visit (P<0.05 except for drowsiness). Symptom response was associated with lower baseline symptom intensity based on PSG criterion but higher baseline symptom intensity based on the traditional minimal clinically important difference definition (P<0.001 for all symptoms). In multivariable analysis, higher PSG and nationality were associated with greater PSG response. Conclusion PSG was ≤3 for a majority of patients. PSG response allows clinicians to tailor treatment goals, while adjusting for individual differences in scale interpretation and factors associated with symptom response.

show abstract

“…(19) The items were also revised: “activity” was replaced with “tiredness/fatigue”; “shortness of breath” was added as a standard item; and “constipation”, “insomnia”, “spiritual distress”, “financial distress” and several other symptoms have been proposed as additional items for assessment. (20–22) When ESAS was used daily, the time frame of assessment was modified to examine the average symptom intensity over the past 24 hours instead of “now” to better capture the fluctuating nature of many symptoms. (23) Several studies have examined patients’ perception of ESAS and highlighted opportunities for improvement.…”

Section: B Past Developmentsmentioning

confidence: 99%

The Edmonton Symptom Assessment System 25 Years Later: Past, Present, and Future Developments

Hui

Bruera

2017

Journal of Pain and Symptom Management

534

428

View full text Add to dashboard Cite

Context Routine symptom assessment represents the cornerstone of symptom management. ESAS is one of the first quantitative symptom assessment batteries that allows for simple and rapid documentation of multiple patient-reported symptoms at the same time. Objective To discuss the historical development of ESAS, its current uses in different settings, and future developments. Methods Narrative review Results Since its development in 1991, ESAS has been psychometrically validated and translated into over 20 languages. We will discuss the variations, advantages and limitations with ESAS. From the clinical perspective, ESAS is now commonly used for symptom screening and longitudinal monitoring in patients seen by palliative care, oncology, nephrology, and other disciplines in both inpatient and outpatient settings. From the research perspective, ESAS has offered important insights into the nature of symptom trajectory, symptom clusters and symptom modulators. Furthermore, multiple clinical studies have incorporated ESAS as a study outcome and documented the impact of various interventions on symptom burden. On the horizon, multiple groups are actively investigating further refinements to ESAS, such as incorporating it in electronic health records, employing ESAS as a trigger for palliative care referral, and coupling ESAS with personalized symptom goals to optimize symptom response assessment. Conclusion ESAS has evolved over the past 25 years to become an important symptom assessment instrument in both clinical practice and research. Future efforts are needed to standardize this tool and explore its full potential to support symptom management.

show abstract

Modified Edmonton Symptom Assessment System Including Constipation and Sleep: Validation in Outpatients With Cancer

Abstract: The ESAS-CS and ESAS-r-CS NRS versions are valid and reliable for measuring symptoms in this population of outpatients with advanced cancer. Although the ESAS-r-CS was preferred, patients favored the 24-hour time window of the ESAS-CS, which also may best characterize fluctuating symptoms.

Cited by 84 publications

References 35 publications

Adherence to guideline‐recommended process measures for squamous cell carcinoma of the head and neck in Ontario: Impact of surgeon and hospital volume

Adherence to guideline‐recommended process measures for squamous cell carcinoma of the head and neck in Ontario: Impact of surgeon and hospital volume

Personalized symptom goals and response in patients with advanced cancer

The Edmonton Symptom Assessment System 25 Years Later: Past, Present, and Future Developments

Contact Info

Product

Resources

About